Navigation Links
Groups Issue New Dementia Drug Guidelines
Date:3/4/2008

Review finds little difference in effectiveness of 5 drugs currently available

TUESDAY, March 4 (HealthDay News) -- There's no proof that any one of the five drugs available in the United States to treat dementia is better than the others, says an American College of Physicians (ACP) and American Academy of Family Physicians (AAFP) committee that just issued a new guideline on drug treatment of dementia.

The committee reviewed published studies for outcomes such as cognition, global function, behavior/mood, and quality of life/activities of daily living. But the committee said it found only limited high-quality scientific evidence about the effectiveness of the drugs and therefore developed the following cautious recommendations:

  • The decision to use approved drugs for dementia should be based on an individualized patient assessment.
  • The choice of drugs should be based on tolerability, adverse effect profile, ease of use, and cost.
  • There's an urgent need for more clinical research to improve knowledge about the clinical effectiveness of drugs treatment for dementia.

The committee recommended the following kinds of research:

  • Evaluate the effectiveness of drug therapy for dementia and assess whether treatments affect key outcomes, such as institutionalization.
  • Evaluate the appropriate duration of therapy.
  • Head-to-head testing of drugs.
  • Test drugs in combination therapy.

The guideline are published in the March 4 issue of the Annals of Internal Medicine.

Currently, there are five FDA-approved drugs for treatment of dementia. These include four acetylcholinesterase inhibitors -- donepezil (Aricept), galantamine (Razadyne, Reminyl, Nivalin), rivastigmine (Exelon), and tacrine -- and one neuropeptide-modifying agent -- memantine (Mamenda).

While these drugs may improve symptoms or slow disease progression, they don't cure dementia or repair brain damage.

"Doctors, patients and family caregivers desperately want information on how to treat this disease," Dr. Amir Qaseem, senior medical associate in the ACP's Clinical Programs and Quality of Care Department, said in a prepared statement. "It is disheartening to find that all we have to work with is these five drugs, and the evidence on these is scant. Consider that in 50 years, one in 45 Americans will suffer from Alzheimer's disease. This is a huge problem."

Most of existing studies of the five approved dementia drugs focused on statistical significance of changes, but clinically important improvement is what matters to patients, caregivers and doctors, the committee noted.

"More research is warranted, because the available evidence concerning these pharmaceuticals' effects on quality of life is mixed, and the clinical significance of many of the findings is questionable," Dr. Kenneth G. Schellhase, an AAFP representative on the committee, said in a prepared statement. "In addition, the duration of existing trials was usually less than one year, providing insufficient information to determine the optimal length of treatment, and few trials compare one drug directly with another."

More information

The Family Caregiver Alliance has more about dementia.



-- Robert Preidt



SOURCE: Annals of Internal Medicine, news release, March 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Atria Bills Get Support From Assisted Living Residents, Family Members, Senior Groups
2. Closer Analysis Shows Consumer Groups Make Gains in Stem Cell Patent Challenges Against WARF; Appeal Still Planned Against Narrowed Claims
3. Hospital Groups United in Opposition to Charity Care Cuts
4. Consumer Groups Will Continue to Press Stem Cell Patent Challenge
5. Alzheimers Foundation of America Awards Grants to Local Groups Nationwide
6. Health Groups Launch Ad Campaign Supporting 70-Cent Increase in Kentucky Cigarette Tax
7. Family, Friends and Support Groups Add Picture Messaging to Inspire and Motivate - Anywhere, Anytime
8. Nations Leading Preventive Health Groups Seek to Save Lives by Transforming Americans Approach to Health
9. Bush Budget Puts Future of Health Care for All Children in Jeopardy, According to National Pediatric Groups
10. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
11. Engaging 2008 Debate, Key Long Term Care Advocacy Groups Offer New Plan to Strengthen Nations Long Term and Post-Acute Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Groups Issue New Dementia Drug Guidelines
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... and other leading institutions in announcing the launch of the Leadership Circle ... way animals are raised for food. , Founding members of the Leadership Circle ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: